Physician profile
David John Pedersen
NPI 1669792339
$5,631.89
in general payments reported to CMS, 2019-2025
30 companies · $726 in 2025
The $726 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,126 · 2022: $2,101 · 2023: $1,504 · 2024: $175 · 2025: $726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,405.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $930.11 | 2021-2023 | Ozempic, Rybelsus |
| Abbvie INC. | $744.27 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $503.33 | 2022-2023 | Farxiga |
| Glaxosmithkline, LLC. | $395.44 | 2022-2023 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $376.65 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $374.32 | 2021 | |
| Lilly USA, LLC | $318.97 | 2021-2023 | Trulicity, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $249.52 | 2022-2023 | |
| Madrigal Pharmaceuticals | $202.74 | 2025 | Rezdiffra |
| Neurocrine Biosciences, INC. | $164.91 | 2022-2023 | Ingrezza |
| Janssen Scientific Affairs, LLC | $150.00 | 2025 | |
| Orphalan INC | $141.72 | 2024 | Cuvrior |
| Biohaven Pharmaceutical Holding Company LTD. | $130.84 | 2022 | |
| Exact Sciences Corporation | $124.87 | 2025 | Cologuard Collection Kit |
| Ucb, INC. | $124.79 | 2025 | Bimzelx |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $118.68 | 2022 | |
| Amgen INC. | $114.41 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.21 | 2023 | Xifaxan, Plenvu, Trulance |
| Merck Sharp & Dohme LLC | $57.50 | 2023 | Dificid |
| Alnylam Pharmaceuticals INC. | $56.00 | 2023-2024 | Onpattro, Givlaari |
| Nestle Healthcare Nutrition INC. | $46.57 | 2023 | |
| Ardelyx, INC. | $33.17 | 2023 | Ibsrela |
| Ferring Pharmaceuticals INC. | $33.13 | 2023 | Rebyota |
| Celgene Corporation | $26.39 | 2023 | Zeposia |
| Janssen Biotech, INC. | $24.98 | 2023 | Remicade, Stelara |
| Braintree Laboratories, INC. | $21.01 | 2023 | Sutab |
| Axsome Therapeutics, INC. | $20.69 | 2022 | |
| Organon LLC | $20.27 | 2023 | Renflexis, Hadlima |
| Daiichi Sankyo INC. | $19.65 | 2023 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $14.75 | 2023 | Entyvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Pedersen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.